Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

An endocrinologist explains the five main types, how they behave, treatment options, and why knowing the exact type can reduce fear and improve outcomes.

Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and liquid biopsies, driven by the rise in hematologic malignancies. The surge ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

DIAMOND BAR, Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Breyanzi provided sustained clinical benefit with a median duration of response not reached. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for income in today’s ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Important facts to keep in mind. re than 30 million Americans have a thyroid disorder and an excess of 60,000 Americans are affected by thyroid cancer annually. — -- intro: You probably don't ...